Focal Cortical Dysplasia Type II : Somatic Mutations, Molecular Mechanisms, and Integrative Multi‐Omics Framework
CNS Neuroscience & Therapeutics · 2026-09 · 32 (9)
DOI: 10.1002/cns.71170 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 23.09.2026. Verfasst von Zesheng Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Mutation, Focal Cortical Dysplasia, Malformations of Cortical Development, Group I. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Science & Technology Commission, Beijing Natural Science Foundation-Daxing Innovation Joint Fund, Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park.
Abstract (Originalsprache)
Background
Focal cortical dysplasia Type II (FCD II) is a major cause of drug‐resistant epilepsy in children. Somatic mosaic variants affecting the PI3K–AKT–mTOR pathway are implicated in a substantial proportion of cases. The links between genotype, cellular pathology, epileptogenic networks, and clinical outcome remain incompletely defined.
Methods
This review synthesizes evidence on somatic mTOR–pathway variants, lesion development, pathological cell populations, circuit mechanisms, single‐cell and spatial multi‐omics approaches in FCD II.
Results
The developmental timing, lineage distribution, and local expansion of somatic variants influence lesion extent and phenotypic heterogeneity. Dysmorphic neurons may contribute to epileptogenicity through altered intrinsic excitability and synaptic function, whereas balloon cells may predominantly affect local circuits through secretory and microenvironmental mechanisms. mTOR hyperactivation may also alter interneuron development, subtype specification, and synaptic connectivity, thereby disrupting excitation‐inhibition balance. Single‐cell and spatial approaches, including RNA velocity, pseudotime analysis, chromatin‐age inference, and somatic genotyping, provide tools to resolve pathological cell states and lineage trajectories.
Conclusions
FCD II should be considered a mosaic developmental disorder involving both cell‐autonomous and non‐cell‐autonomous mechanisms. Integrating somatic variant detection with cellular, spatial, electrophysiological, and surgical outcomes from matched patient tissue may enable biologically meaningful stratification and support the development of novel therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Clinical Research Center for Epilepsy, Capital Medical University, Beijing, China.
- China International Neuroscience Institute, Beijing, China.
ORCID-Profile: Zesheng Li, Yihe Wang, Jianwei Shi, Yumin Luo, Yongzhi Shan, Guoguang Zhao
Förderung
- Beijing Municipal Science & Technology Commission
- Beijing Natural Science Foundation-Daxing Innovation Joint Fund
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
Zitieren
APA
Li, Z., Wang, Y., Shi, J., Luo, Y., Shan, Y., & Zhao, G. (2026). Focal Cortical Dysplasia Type II : Somatic Mutations, Molecular Mechanisms, and Integrative Multi‐Omics Framework. CNS Neuroscience & Therapeutics, 32(9). https://doi.org/10.1002/cns.71170
Vancouver
Li Z, Wang Y, Shi J, Luo Y, Shan Y, Zhao G. Focal Cortical Dysplasia Type II : Somatic Mutations, Molecular Mechanisms, and Integrative Multi‐Omics Framework. CNS Neuroscience & Therapeutics. 2026;32(9). doi:10.1002/cns.71170
BibTeX
@article{Li2026,
author = {Li, Zesheng and Wang, Yihe and Shi, Jianwei and Luo, Yumin and Shan, Yongzhi and Zhao, Guoguang},
title = {Focal Cortical Dysplasia Type II : Somatic Mutations, Molecular Mechanisms, and Integrative Multi‐Omics Framework},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {9},
doi = {10.1002/cns.71170}
}
EUVIMED